WO2014191117A1 - Agent cosmétique de soin cutané contenant de la purine ou de la taurine - Google Patents

Agent cosmétique de soin cutané contenant de la purine ou de la taurine Download PDF

Info

Publication number
WO2014191117A1
WO2014191117A1 PCT/EP2014/052017 EP2014052017W WO2014191117A1 WO 2014191117 A1 WO2014191117 A1 WO 2014191117A1 EP 2014052017 W EP2014052017 W EP 2014052017W WO 2014191117 A1 WO2014191117 A1 WO 2014191117A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
skin
add
purine
cosmetic
Prior art date
Application number
PCT/EP2014/052017
Other languages
German (de)
English (en)
Inventor
Daniela KEßLER-BECKER
Markus Semrau
Thomas Förster
Original Assignee
Henkel Ag & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Ag & Co. Kgaa filed Critical Henkel Ag & Co. Kgaa
Publication of WO2014191117A1 publication Critical patent/WO2014191117A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • the invention relates to topical cosmetic or dermatological compositions for skin treatment.
  • Aging skin changes the texture of its uppermost layer, the epidermis, as the aging process progresses. This gets thinner and the connections between the cells relax. Due to these changes, the aging skin becomes particularly vulnerable to external influences such as mechanical stress. The skin is more sensitive to external stimuli, dries faster and becomes flaky. Decreased moisture retention and high transepidermal water loss contribute to the enhancement of age-related skin lesions.
  • a first subject of this application are cosmetic or dermatological topical compositions containing in a suitable cosmetic or dermatological carrier a) polylactic acid particles and
  • At least one active ingredient selected from purine, purine derivatives and / or taurine (2-aminoethanesulfonic acid).
  • a first essential component of the cosmetic compositions according to the invention are the polylactic acid particles a).
  • the use of polylactic acid particles in cosmetics is
  • the proportion by weight of polylactic acid particles a) in the total weight of cosmetic compositions according to the invention is preferably from 0.1 to 20% by weight, preferably 0.5 to 15 wt .-%, particularly preferably 0.75 to 10 wt .-% and in particular 1 to 8 wt .-%.
  • Polylactic acid also called polylactide or PLA
  • PLA is a term for biodegradable polymers (polyesters), which are mainly accessible by the ionic polymerization of lactide, an annular combination of two lactic acid molecules.
  • Lactic acid are produced. In industrial production, however, the disposal of the
  • the lactic acid (2-hydroxypropanoic acid) has an asymmetric carbon atom, so that the polylactic acid also has optically active centers in L (+) and D (-) configuration.
  • the ratio of L to D monomer units determines the degree of crystallinity, the melting point and the biodegradability of the polymers.
  • Polylactic acids suitable according to the invention are L-polylactic acid, D-polylactic acid and L / D-polylactic acid and mixtures thereof. Because of its very good biodegradability, L-polylactic acid is particularly preferred. In a preferred embodiment of the present invention, the weight fraction of L-lactic acid monomer units in the polylactic acid is greater than 50% by weight, preferably greater than 80% by weight and in particular greater than 90% by weight.
  • the molar mass of the polylactic acid suitable according to the invention is preferably from 1000 to 1,000,000, preferably from 10,000 to 300,000, more preferably from 50,000 to 250,000 and in particular from 100,000 to 180,000 daltons.
  • the polylactic acid is used in a form veneered with fillers.
  • fillers The use of larger amounts of filler helps to comminute the polymer into particles, increases biodegradability and internal specific surface area through porosity and capillarity.
  • water-soluble fillers are particularly preferred, such as metal chlorides such as NaCl, KCl, etc., metal carbonates such as Na 2 C0 3, NaHC0 3, etc., metal sulfates such as MgS0. 4
  • fillers and natural raw materials can be used, for example, nut shells, wood or bamboo fibers, starch, xanthan gum, alginates, dextran, agar, etc. These fillers are biological degradable and do not degrade the good ecological properties of polylactic acid particles.
  • the content of biodegradable fillers in the polylactic acid particles can be from 10 to 70% by weight, with amounts of from 20 to 60 being preferred, and those of from 30 to 50% by weight being particularly preferred.
  • Polylactic acid particles which are suitable according to the invention can be present both in spherical form and as irregular particles which have a certain circularity.
  • the polylactic acid particles may preferably have a circularity between 0.1 and 0.6.
  • polylactic acid particles of lower circularity may be preferred if a less abrasive, gentler abrasive action of the cleaning agent according to the invention is to be achieved.
  • the shape of the polylactic acid particles used according to the invention can be defined in various ways, in the context of this preferred embodiment of the present invention, the geometric proportions of a particle and - pragmatic - a particle population are determined.
  • the polylactic acid particles used according to the invention preferably have sizes which, by their area equivalent diameter (ISO 9276-6: 2008 (E) section 7), are also called "Equivalent Circle Diameter ECD" (ASTM F1877-05 Section 11 .3.2
  • the mean ECD of a particle population is calculated as the average ECD of each individual particle of a particle population of at least 10,000 particles, preferably more than 50,000 particles, more preferably more than 100,000 particles, after particles with one particle size Area equivalent diameter (ECD) below 10 [im were excluded from the measurement.
  • the polylactic acid particles have average ECD values of from 10 to 1000 [im, preferably from 50 to 500 [im, more preferably from 100 to 350 [im and in particular from 150 to 250 [im.
  • cosmetic cleansing compositions according to the invention are preferred in which the polylactic acid particles have absolute particle sizes of from 1 to 1000 ⁇ m, more preferably from 1 to 850 ⁇ m, particularly preferably from 1 to 750 ⁇ m, very preferably from 1 to 500 ⁇ m [im and particularly preferably from 1 to 300 [im have.
  • form descriptors are used, which are calculations from geometric descriptors or form factors.
  • Form factors are relationships between two different geometric properties, which in turn
  • Proportions of an ideal geometric body enclosing the particle are.
  • meso-form descriptors are used for particle characterization. These meso shape descriptors indicate to what extent a particle deviates from an ideal geometric shape, in particular from a sphere.
  • the polylactic acid particles may be of the typical spherical or spherical shape such as
  • Differ granulate particles (see above).
  • the particles preferably have sharp corners and edges and preferably have concave indentations.
  • Sharp corners of non-spherical particles may be defined by a radius of less than 20 [im, preferably less than 8 [im, and especially less than 5 [im, where the radius is defined as the radius of an imaginary circle following the contour of the comer.
  • Circularity is a quantitative 2-dimensional image analysis and can be determined according to ISO 9276-6: 2008 (E) section 8.2. Circularity is a preferred meso-form descriptor and can be determined, for example, with the "Occhio Nano 500 Particle Characterization Instrument” described above with the "Callistro version 25" software (Occhio sa vide, Belgium) or with the "Malvern Morphologi G3". Circularity is sometimes described in the literature as the difference between a particle and the perfect sphere.
  • polylactic acid particles having an average circularity C of from 0.1 to 0.6, preferably from 0.15 to 0.4, and in particular from 0.2 to 0.35, have been described in the context of the present invention proved particularly suitable.
  • the mean values are obtained by quotient formation from volume-based measurements and number-based measurements.
  • Solidity is a quantitative 2-dimensional image analysis and can be determined according to ISO 9276-6: 2008 (E) section 8.2. Solidity is also a preferred meso-form descriptor and can be determined, for example, with the "Occhio Nano 500 Particle Characterization Instrument” described above using the "Callistro version 25" software (Occhio, supra, Med, Belgium) or "Malvern Morphologi G3". Solidity is a meso-form descriptor that describes the concavity of a particle or particle aggregate. The values for solidity vary between 0 and 1, where 1 describes a non-concave particle:
  • Solidity A / Ac where A is the (image) area of the particle and Ac is the area of the convex hull enclosing the particle.
  • polylactic acid particles having an average solidity of from 0.4 to 0.9, preferably from 0.5 to 0.8 and especially from 0.55 to 0.65 have been found to be particularly useful in the present invention proved.
  • the mean values are obtained by quotient formation from volume-based measurements and number-based measurements.
  • Particularly preferred polylactic acid particles of the first preferred embodiment preferably have an average circularity C of from 0.1 to 0.6, preferably from 0.15 to 0.4 and in particular from 0.2 to 0.35 and an average solidity of 0, 4 to 0.9, preferably from 0.5 to 0.8 and in particular from 0.55 to 0.65.
  • the "mean" circularities and solidities are averages from the measurement of a large number of particles, usually more than 10,000 particles, preferably more than 50,000 particles, and especially more than 100,000 particles, with particles of area equivalent diameter (ECD) below 10 ⁇ were excluded from the measurement.
  • the polylactic acid polymer After its preparation, the polylactic acid polymer can be converted to the desired particle size and shape, for example by milling, depending on which mold is needed for which purpose.
  • a particularly preferred process for preparing polylactic acid particles of desired circularity and solidity is to produce a foam of polylactic acid and subsequent grinding.
  • the polylactic acid particles may further be advantageous for the polylactic acid particles to cure from 3 to 50 kg / mm 2 , preferably from 4 to 25 kg / mm 2 and especially from 5 to 15 kg / mm 2 on the HV Vickers hardness scale.
  • the hardness of the particles can be varied by the ratio of D to L monomers and the molecular weight.
  • Polylactic acid particles that can be used with preference in the inventive cleaning compositions are commercially available (for example, by the company Micro Powders, Inc. under the trade names Ecosrub ®). Particularly preferred are the commercial products Ecosrub ® 20PC, 50PC Ecosrub ®, Ecosrub ® 100PC, Ecoblue ® 5025 and Ecogreen ® 5025. Particularly preferred Ecosrub ® 20PC and Ecosrub ® 50PC are.
  • the compositions of the invention contain at least one active ingredient b) selected from purine, purine derivatives and / or taurine (2-aminoethanesulfonic acid).
  • the proportion by weight of the active substance b) in the total weight of the cosmetic compositions is preferably from 0.001 to 10% by weight, preferably from 0.005 to 7.5% by weight, particularly preferably from 0.01 to 5% by weight and in particular from 0.05 to 3 wt .-%.
  • Preferred cosmetic compositions are characterized in that they contain, based on their weight, a) from 0.1 to 20% by weight, preferably from 0.5 to 15% by weight, more preferably from 0.75 to 10% by weight, and in particular 1 to 8 wt .-% polylactic acid particles, and b) 0.001 to 10 wt .-%, preferably 0.005 to 7.5 wt .-%, particularly preferably 0.01 to 5 wt .-% and in particular 0.05 to 3 wt .-% purine, purine derivatives and / or taurine (2-aminoethanesulfonic acid).
  • Purine and / or purine derivative (s) are, in each case based on the total agent, preferably in amounts of 0.0005 to 5.0 wt .-%, preferably 0.001 to 3.0 wt .-%, particularly preferably 0.01 to 2.0 wt .-% and particularly preferably 0.1 to 1, 5 wt .-% used.
  • the agents preferably contain purine and / or purine derivative (s) of the formula (I)
  • radicals R, R 2 and R 3 are independently selected from -H, - OH, -NH 2 , -SH and the radicals R 4 , R 5 and R 6 are independently selected from -H, -CH 3 and -CH 2 -CH 3 .
  • Purine (7H-imidazo [4,5-d] pyrimidine) does not occur freely in nature, but forms the main body of the purines.
  • Purines are a group of important compounds naturally involved in human, animal, plant and microbial metabolic processes which are different from the parent by substitution with OH, NH 2 , SH at the 2-, 6-, and 8-positions and / or with CH 3 in 1-, 3-, 7-position derived.
  • Purine can be prepared, for example, from aminoacetonitrile and formamide.
  • Purines and purine derivatives are often isolated from natural products, but are also synthetically accessible in many ways.
  • Suitable compounds of the formula (I) are in particular:
  • Purine derivatives of the formula (I) wherein R and R 2 are --OH and R 3 is -H are also referred to as xanthine and / or xanthine derivatives.
  • the agents according to the invention preferably contain, as purine derivatives, xanthine and / or xanthine derivatives.
  • agents according to the invention contain caffeine as purine and / or purine derivative.
  • agents of the invention may also contain several components selected from purine and purine derivatives, again preferred combinations containing caffeine.
  • Taurine (2-aminoethanesulfonic acid) is, in each case based on the total agent, preferably in amounts of 0.001 to 5.0 wt .-%, preferably 0.01 to 4.0 wt .-%, particularly preferably 0.1 to 3, 0 wt .-% and particularly preferably used 0.2 to 2.0 wt .-%.
  • compositions according to the invention are characterized in that they contain as active ingredient b) a mixture of purine and / or purine derivatives and taurine (2-aminoethanesulfonic acid). It is particularly preferred to use as active ingredient b) a mixture of caffeine and taurine (2-aminoethanesulfonic acid).
  • compositions according to the invention contain the active ingredient combination a) and b) in a suitable cosmetic carrier.
  • a topical carrier which is preferably an aqueous or aqueous-alcoholic carrier.
  • the carrier contains - based to its total weight - at least 20 wt .-%, more preferably at least 25 wt .-% particularly preferably at least 30 wt .-% and in particular at least 35 wt .-% water.
  • Particularly preferred cosmetic compositions are characterized by a water content between 30 and 90 wt .-%, preferably 50 to 90 wt .-%, particularly preferably 60 to 85 wt .-% and in particular 65 to 85 wt .-%.
  • the cosmetic carrier may contain from 0.01 to 40% by weight, preferably from 0.05 to 35% by weight and in particular from 0.1 to 30% by weight, of at least one alcohol which may be selected from ethanol, Propanol, 2-propanol, isopropanol, glycerol, diglycerol, triglycerol, 1-butanol, 2-butanol,
  • ethanol particularly preferred are ethanol, 1-propanol, 2-propanol, 1, 2-propylene glycol, glycerol, and / or 1, 6-hexanediol and mixtures of these alcohols.
  • glycerol and / or 1,6-hexanediol particularly preferred are glycerol and / or 1,6-hexanediol.
  • Preferred cosmetic compositions contain 0.1 to 20 wt .-%, preferably 0.5 to 15 wt .-%, particularly preferably 1 to 10 wt .-%, and in particular 2 to 8 wt .-% of at least one polyol selected from Glycerine, 1,2-propylene glycol,
  • Particularly suitable emulsions according to the invention preferably comprise at least one further skin-conditioning agent e) and / or at least one emulsifier d) in addition to the active substances already described.
  • Suitable skin-conditioning active ingredients c) are preferably those substances which are applied to keratinic materials, in particular to the skin, and which
  • Preferred skin conditioning agents c) can be selected from fatty substances, in particular vegetable oils, such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons, di-n-alkyl ethers having a total of 12 to 36 carbon atoms, z.
  • vegetable oils such as sunflower oil, olive oil, soybean oil, rapeseed oil, almond oil, jojoba oil, orange oil, wheat germ oil, peach kernel oil and the liquid portions of coconut oil, lanolin and its derivatives, liquid paraffin oils, isoparaffin oils and synthetic hydrocarbons, di-n-alkyl ethers having a total of 12 to 36 carbon atoms, z.
  • B di-n-octyl ether and n-hexyl-n-octyl ether, fatty acids, especially linear and / or branched, saturated and / or unsaturated C 8 . 30- fatty acids, fatty alcohols, particularly saturated, mono- or polyunsaturated, branched or unbranched
  • Fatty alcohols having 4-30 carbon atoms which may be ethoxylated with 1-75, preferably 5-20 ethylene oxide units and / or propoxylated with 3-30, preferably 9-14 propylene oxide units, ester oils, ie esters of C 6 . 30 fatty acids with C 2 -3o-fatty alcohols,
  • Hydroxycarboxylic acid alkyl esters dicarboxylic acid esters such as di-n-butyl adipate and diol esters such as ethylene glycol dioleate or propylene glycol di (2-ethylhexanoate), symmetrical, unsymmetrical or cyclic esters of carbonic acid with fatty alcohols, eg. B. glycerol carbonate or dicaprylyl carbonate (Cetiol ® CC), mono, - di- and tri fatty acid esters of saturated and / or unsaturated linear and / or branched fatty acids with glycerol, which, preferably 7- 9 ethylene oxide units may be ethoxylated with 1 -10, z.
  • dicarboxylic acid esters such as di-n-butyl adipate and diol esters such as ethylene glycol dioleate or propylene glycol di (2-ethylhexanoate
  • compositions of the invention contain a mixture of skin conditioning agents from the aforementioned list.
  • Compositions is preferably from 1, 0 to 50 wt .-%, preferably 1, 0 to 30 wt .-%, particularly preferably 2.0 to 20 wt .-% and in particular 2.0 to 10 wt .-% of at least one skin-conditioning agent c), wherein the amounts are based on the weight of the cosmetic compositions.
  • Suitable surface-active substances and / or emulsifiers d) are, for example, addition products of 4 to 30 mol of ethylene oxide and / or 0 to 5 mol of propylene oxide onto linear C 8 -C 2 2- Fatty alcohols, at C
  • Fatty acid alkanolamides and fatty acid glucamides C 8 -C 2 2-alkyl mono- and oligoglycosides and their ethoxylated analogues, with degrees of oligomerization of 1, 1 to 5, in particular 1, 2 to 2.0, and glucose are preferred as the sugar component, for example those under the under the INCI name Coco Glucoside known product, mixtures of alkyl (oligo) glucosides and fatty alcohols, eg.
  • As the commercially available products Montanov ® 68 and Montanov ® 202 addition products of 5 to 60 moles of ethylene oxide with castor oil and hydrogenated castor oil, partial esters of polyols 3-6
  • Carbon atoms with saturated C 8 -C 2 fatty acids sterols, in particular cholesterol, lanosterol, beta-sitosterol, stigmasterol, campesterol and ergosterol and mycosterols,
  • Phospholipids especially glucose phospholipids, fatty acid ester of sugars and sugar alcohols such as sorbitol, polyglycerols and polyglycerol, preferably Polyglyceryl-2-dipolyhydroxystearate (commercial product Dehymuls ® PGPH) and polyglyceryl-3-diisostearate (commercial product Lameform ® TGI) as well as linear and branched C 8 C 30 fatty acids and their Na, K, ammonium, Ca, Mg and Zn salts.
  • sorbitol sorbitol
  • polyglycerols and polyglycerol preferably Polyglyceryl-2-dipolyhydroxystearate (commercial product Dehymuls ® PGPH) and polyglyceryl-3-diisostearate (commercial product Lameform ® TGI) as well as linear and branched C 8 C 30 fatty acids and their Na, K, ammonium, Ca, Mg and Zn salts.
  • particularly preferred O / W emulsifier system comprises a mixture of
  • Dipotassium monocetyl phosphate and potassium dicetyl phosphate with hardened palm oil glycerides A corresponding mixture is obtainable from Symrise as a commercial product "Emulsiphos 677660" (INCI: Potassium Cetyl Phosphate, Hydrogenated Palm Glycerides) .
  • Preferred compositions of the invention contain, based on their total weight, 0.1 to 3.0% by weight, preferably 0.2 to 2.0 wt .-% and in particular 0.5 to 1, 5 wt .-% of a nonethoxylated anionic O / W emulsifier, preferably a mixture of dipotassium monocetyl phosphate and potassium dicetyl phosphate with hardened palm oil glycerides.
  • compositions according to the invention may contain the emulsifiers d) preferably in amounts of from 0.1 to 25% by weight, more preferably from 0.5 to 15% by weight and in particular from 1 to 10% by weight, based on the total composition , contain.
  • compositions according to the invention are provided.
  • Skin-soothing active ingredients preferred according to the invention are selected from allantoin, ⁇ -bisabolol, ⁇ -lipoic acid, extracts from Centella asiatica, for example obtainable under the name Madecassicoside from DSM, glycyrrethic acid, which are particularly preferred in liposomes encapsulated present and in this form z.
  • Skin-soothing active ingredients preferred according to the invention are selected from allantoin, ⁇ -bisabolol, ⁇ -lipoic acid, extracts from Centella asiatica, for example obtainable under the name Madecassicoside from DSM, glycyrrethic acid, which are particularly preferred in liposomes encapsulated present and in this form z. B.
  • Trade name Vanirea (INCI: Vanilla Tahitensis Fruit Extract) are available from Solabia, Alginhydrolysaten as z. B. under the trade name phycosaccharides, in particular phycosaccharides AI, are available from the company Codif, extracts of Bacopa Monniera, as described, for. B. under the trade name Bacocalmine available from the company Sederma, extracts from the Rooibos plant, as described, for. B.
  • Rooibos Herbasec MPE available from the company Cosmetochem, yeast extracts, particularly preferably the commercial product Drieline (INCI name "sorbitol, Yeast Extract"), available from Lanatech, the physiologically acceptable salts of sterol sulfates, as described, for , B.
  • the skin-calming active ingredients e) are preferably in a total amount of 0.001 to 5 wt .-%, particularly preferably 0.01 to 2 wt .-% and most preferably 0.1 to 1 wt .-%, each based on the total composition, contain.
  • emulsions and / or aqueous gels are thickeners, for.
  • anionic polymers of acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropansulfonsaeure wherein the acidic groups may be wholly or partially present as sodium, potassium, ammonium, mono- or triethanolammonium salt and at least one may be included nonionic monomer.
  • Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.
  • Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. These copolymers can also be present in crosslinked form. Suitable commercial products are NS Sepigel ® 305, Simulgel ® 600, Simulgel ® and Simulgel EPG ® of the company SEPPIC. Further particularly preferred anionic homopolymers and copolymers are uncrosslinked and crosslinked
  • Polyacrylic Such compounds are for example the commercial products Carbopol ®.
  • a particularly preferred anionic copolymer contains as monomer 80-98% of an unsaturated, optionally substituted C 3 _ 6 -carboxylic acid or its anhydride as well as 2-20% optionally substituted acrylate of saturated Ci 0 -3o-carboxylic acids, which copolymer may be crosslinked with the foregoing crosslinking agents.
  • Corresponding commercial products are Pemulen ® and Carbopol ® grades 954, 980, 1342 and ETD 2020 (ex BF Goodrich).
  • compositions according to the invention with the active ingredient complex according to the invention are vitamins, provitamins or vitamin precursors.
  • Vitamins, pro-vitamins and vitamin precursors are particularly preferred, which are assigned to the groups A, B, C, E, F and H.
  • vitamin A includes retinol and 3,4-didehydroretinol.
  • Beta-carotene is the provitamin of retinol.
  • vitamin A component according to the invention for example, vitamin A acid and its esters, vitamin A aldehyde and vitamin A alcohol and its esters such as the palmitate and the acetate into consideration.
  • agents according to the invention contain the vitamin A component preferably in amounts of 0.05-1 wt .-%, based on the total preparation.
  • the vitamin B group or the vitamin B complex include u. a .:
  • Vitamin B-1 (thiamine)
  • Vitamin B-2 (riboflavin)
  • Vitamin B-3 Under this name are often the compounds nicotinic acid and
  • Nicotinic acid amide (niacinamide).
  • Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.
  • Vitamin B-5 (pantothenic acid, panthenol and pantolactone). Panthenol and / or pantolactone are preferably used in the context of this group. Derivatives of the invention which can be used according to the invention
  • Panthenols are in particular the esters and ethers of panthenol as well as cationically derivatized panthenols. Individual representatives are, for example, panthenol triacetate, the
  • Panthenol monoethyl ether and its monoacetate and cationic panthenol derivatives Panthenol monoethyl ether and its monoacetate and cationic panthenol derivatives.
  • Pantothenic acid is preferably used as a derivative in the form of the more stable calcium salts and sodium salts (Ca-pantothenate, Na-pantothenate) in the present invention.
  • Vitamin B-6 pyridoxine and pyridoxamine and pyridoxal.
  • the said compounds of the vitamin B type are preferably present in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0.1-5 wt .-% are particularly preferred.
  • Vitamin C (ascorbic acid). Vitamin C is used in the inventive compositions preferably in amounts of 0, 1 to 3 wt .-%, based on the total agent.
  • Palmitic acid ester, glucosides or phosphates may be preferred.
  • the use in Combination with tocopherols may also be preferred.
  • Vitamin E tocopherols, especially .alpha.-tocopherol.
  • Tocopherol and its derivatives which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.
  • Vitamin F is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.
  • Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-d] - imidazole-4-valeric acid, for which, however, the common name biotin has meanwhile prevailed.
  • Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.
  • compositions according to the invention preferably contain vitamins, provitamins and vitamin precursors from groups A, B, E and / or H. Panthenol, pantolactone, pyridoxine and derivatives as well as nicotinamide and biotin are particularly preferred.
  • compositions according to the invention are preferably characterized by a high content of natural and / or biodegradable ingredients.
  • Preferred cosmetic compositions are characterized in that they contain 40 to 100% by weight, preferably 45 to 99% by weight, particularly preferably 50 to 97% by weight and in particular 60 to 95% by weight of active ingredients of natural origin are and / or are biodegradable, the amounts being based on the weight of the cosmetic compositions without the aqueous and alcoholic solvents contained in these compositions.
  • composition of some preferred cosmetic compositions can be seen from the following tables (in wt .-% based on the total weight of
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Formula 6 Formula 7
  • Formula 8 Formula 9
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Purine / purine derivative 0.001 to 5.0 0.001 to 3.0 0.01 to 2.0 0.01 to 1.5, 0.1 to 1.5 Mise add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0 active ingredient b) 0.001 to 10 0.005 to 7.5 0.01 to 5.0 0, 05 to 3.0 0.05 to 3.0 skin conditioning 1, 0 to 50 1, 0 to 30 2.0 to 20 2.0 to 15 2.0 to 10 active ingredient c)
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Purine / purine derivative 0.001 to 5.0 0.001 to 3.0 0.01 to 2.0 0.01 to 1.5, 0.1 to 1.5
  • Skin conditioning 1, 0 to 50 1, 0 to 30, 2.0 to 20, 2.0 to 15, 2.0 to 10
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0 Taurine 0.001 to 5.0 0.01 to 4.0 0.1 to 3.0 0.2 to 3.0 0.2 to 2.0
  • Skin conditioning 1, 0 to 50 1, 0 to 30, 2.0 to 20, 2.0 to 15, 2.0 to 10
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0 active ingredient b) 0.001 to 10 0.01 to 7.5 0.05 to 5.0 0.05 to 5.0 0.1 to 3.0 Ester Oil 1, 0 to 50 1, 0 to 30 2.0 to 20 2.0 to 15 2.0 to 10 Mise add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100 add 100
  • Polyol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Purine / purine derivative 0.001 to 5.0 0.001 to 3.0 0.01 to 2.0 0.01 to 1.5, 0.1 to 1.5
  • Polyol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Polyol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Skin conditioning 1, 0 to 50 1, 0 to 30, 2.0 to 20, 2.0 to 15, 2.0 to 10
  • Polyol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Purine / purine derivative 0.001 to 5.0 0.001 to 3.0 0.01 to 2.0 0.01 to 1.5, 0.1 to 1.5
  • Skin conditioning 1, 0 to 50 1, 0 to 30, 2.0 to 20, 2.0 to 15, 2.0 to 10
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Skin conditioning 1, 0 to 50 1, 0 to 30, 2.0 to 20, 2.0 to 15, 2.0 to 10
  • Polyol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Ester oil 1 0 to 50 1, 0 to 30 2.0 to 20 2.0 to 15 2.0 to 10
  • Polyol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Skin conditioning 1, 0 to 50 1, 0 to 30, 2.0 to 20, 2.0 to 15, 2.0 to 10
  • Glycerol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Purine / purine derivative 0.001 to 5.0 0.001 to 3.0 0.01 to 2.0 0.01 to 1.5, 0.1 to 1.5
  • Ester oil 1 0 to 50 1, 0 to 30 2.0 to 20 2.0 to 15 2.0 to 10
  • Polyol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Purine / purine derivative 0.001 to 5.0 0.001 to 3.0 0.01 to 2.0 0.01 to 1.5, 0.1 to 1.5
  • Ester oil 1 0 to 50 1, 0 to 30 2.0 to 20 2.0 to 15 2.0 to 10
  • Glycerol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Ester oil 1 0 to 50 1, 0 to 30 2.0 to 20 2.0 to 15 2.0 to 10
  • Glycerol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Purine / purine derivative 0.001 to 5.0 0.001 to 3.0 0.01 to 2.0 0.01 to 1.5, 0.1 to 1.5
  • Skin conditioning 1, 0 to 50 1, 0 to 30, 2.0 to 20, 2.0 to 15, 2.0 to 10
  • Polyol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • Polylactic acid particles 0.1 to 20 0.5 to 15 0.75 to 10 1, 0 to 8.0 1, 0 to 8.0
  • Purine / purine derivative 0.001 to 5.0 0.001 to 3.0 0.01 to 2.0 0.01 to 1.5, 0.1 to 1.5
  • Skin conditioning 1, 0 to 50 1, 0 to 30, 2.0 to 20, 2.0 to 15, 2.0 to 10
  • Glycerol 0.1 to 20 0.5 to 15 1, 0 to 10 2.0 to 8.0 2.0 to 8.0
  • the cosmetic compositions according to the invention are distinguished by an unexpected nourishing and regenerating action. Another object of the present application is therefore the use of inventive compositions for non-therapeutic, cosmetic treatment of human skin, in particular
  • Another object of the present application is a non-therapeutic method for non-therapeutic, cosmetic treatment of the human skin, in particular for tightening the skin, to increase the skin moisture and / or to improve the appearance of the skin, characterized in that a composition of the invention to the Skin is applied.
  • the compositions according to the invention can remain on the skin after the application ("leave on") or be removed from the skin after a contact time ("rinse off”).
  • the contact time of the latter products is preferably between 10 and 600 seconds, preferably between 20 and 420 seconds and in particular between 30 and 300 seconds.
  • the following skin creams were prepared (in% by weight):
  • Emulsiphos 677660 (INCI name: Potassium Cetyl Phosphates, Hydrogenated Palm Glycerides), Symrise; Cutina ® MD (INCI name: Glyceryl Stearate), BASF; CetioP A (INCI name: Hexyl Laurate), BASF; Tego Carbomer 140 (INCI name: Carbomer), Evonik; Hydrai / ance ® (INCI name: Hydroxyethyl Urea), Akzo Nobel; Ecoscrub ® 50PC (INCI name: Polylactic Acid), Micro Powders, Inc .; Fucocert ® (INCI name: Biosaccharide Gum-1), Solabia; Dimethicone 5 cSt (INCI name: Dimethicone), Dow Corning; Dow Corning ® 9047 (INCI name: Dimethicone, Dimethicone Crosspolymer), Dow Corning; Phenonip ME ® (INCI name: phenoxyethanol,

Landscapes

  • Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne des compositions cosmétiques ou dermatologiques contenant, dans un véhicule cosmétique ou dermatologique approprié, a) des particules d'acide polylactique et b) au moins une substance active choisie parmi la purine, des dérivés de purine et/ou de la taurine (acide 2-aminoéthanesulfonique). Ces compositions se caractérisent par une action cutanée soignante et raffermissante inattendue.
PCT/EP2014/052017 2013-05-28 2014-02-03 Agent cosmétique de soin cutané contenant de la purine ou de la taurine WO2014191117A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE201310209897 DE102013209897A1 (de) 2013-05-28 2013-05-28 Kosmetisches Hautpflegemittel
DE102013209897.9 2013-05-28

Publications (1)

Publication Number Publication Date
WO2014191117A1 true WO2014191117A1 (fr) 2014-12-04

Family

ID=50030316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/052017 WO2014191117A1 (fr) 2013-05-28 2014-02-03 Agent cosmétique de soin cutané contenant de la purine ou de la taurine

Country Status (2)

Country Link
DE (1) DE102013209897A1 (fr)
WO (1) WO2014191117A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918680B2 (en) 2015-12-31 2024-03-05 Colgate-Palmolive Company Cleansing compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US20110287105A1 (en) * 2010-05-24 2011-11-24 Micro Powders, Inc. Composition comprising biodegradable polymers for use in a cosmetic composition
DE102011084904A1 (de) * 2011-10-20 2012-06-14 Henkel Ag & Co. Kgaa Hautstraffende kosmetische Zusammensetzungen mit verbessertem Hautgefühl
WO2012177617A1 (fr) 2011-06-20 2012-12-27 The Procter & Gamble Company Composition liquide de nettoyage et/ou de purification

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US20110287105A1 (en) * 2010-05-24 2011-11-24 Micro Powders, Inc. Composition comprising biodegradable polymers for use in a cosmetic composition
WO2012177617A1 (fr) 2011-06-20 2012-12-27 The Procter & Gamble Company Composition liquide de nettoyage et/ou de purification
WO2012177615A1 (fr) 2011-06-20 2012-12-27 The Procter & Gamble Company Composition liquide de nettoyage et/ou de purification
DE102011084904A1 (de) * 2011-10-20 2012-06-14 Henkel Ag & Co. Kgaa Hautstraffende kosmetische Zusammensetzungen mit verbessertem Hautgefühl

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BODMEIER R ET AL: "EVALUATION OF BIODEGRADABLE POLY(LACTIDE) PELLETS PREPARED BY DIRECT COMPRESSION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 78, no. 10, 1 October 1989 (1989-10-01), pages 819 - 822, XP009003483, ISSN: 0022-3549, DOI: 10.1002/JPS.2600781008 *
KADER A ET AL: "EFFECT OF PHYSICOCHEMICAL FACTORS ON THE RELEASE KINETICS OF HYDROPHILIC DRUGS FROM POLY(L-LACTIC ACID)(L-PLA) PELLETS", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US, vol. 24, no. 6, 1 January 1998 (1998-01-01), pages 535 - 539, XP008001885, ISSN: 0363-9045, DOI: 10.3109/03639049809085654 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918680B2 (en) 2015-12-31 2024-03-05 Colgate-Palmolive Company Cleansing compositions

Also Published As

Publication number Publication date
DE102013209897A1 (de) 2014-12-04

Similar Documents

Publication Publication Date Title
DE60218698T2 (de) Kosmetische zusammensetzung mit hautstraffender wirkung
EP2352484A1 (fr) Agents de conditionnement des cheveux contenant des imidazolines et des huiles-esters
EP3003502A1 (fr) Gommage cosmétique pour le visage et le corps
DE102004032734A1 (de) Präbiotisch wirksame Substanzen für Deodorantien
WO2020114793A1 (fr) Émulsion h/e contenant des rhamnolipides
DE102009045606A1 (de) Sensitives Haarreinigungsmittel
DE102016209964A1 (de) Cold Cream enthaltende stabile kosmetische Reinigungszusammensetzungen
DE102014225083A1 (de) Haarbehandlungsmittel mit Antischuppenwirkung
EP2556823A2 (fr) Produit de nettoyage renforçant la barrière cutanée comprenant un ferment basé sur des microorganisms probiotiques
DE60000236T3 (de) Reinigende kosmetische zusammensetzungen und ihre verwendung
EP3003257A1 (fr) Procédé de production d'un agent nettoyant cosmétique
EP1813252A1 (fr) Composition cosmétique pour la matage du cuir chevelu
DE10113446A1 (de) Haarbehandlungsmittel mit Betainen
EP2272499B1 (fr) Produits de coiffage apportant une tenue forte en atmosphère humide
EP3003503A1 (fr) Soin cosmétique cutané
WO2014191117A1 (fr) Agent cosmétique de soin cutané contenant de la purine ou de la taurine
WO2014023492A2 (fr) Gel capillaire transparent à une seule phase
WO2013091974A2 (fr) Utilisation d'une combinaison d'acide 2-méthyl-1,4,5,6-tétrahydro-4 pyrimidine carboxylique ou de son dérivé et d'un extrait d'algues bleues pour augmenter la fonction barrière de la peau
WO2016071187A1 (fr) Lotion de douche
DE102010062612A1 (de) Haarbehandlungsmittel
EP2745832B1 (fr) Produit de soin cutané pour le traitement des peaux matures
EP4041412B1 (fr) Préparation de nettoyage contenant de la gomme de caesalpinia spinosa
EP3215113A1 (fr) Lotions de douche
DE102015202971A1 (de) Körperreinigungsmittel enthaltend eine hautpflegende Pflanzenmilch
DE102018221132A1 (de) Alaune und Tenside enthaltende, Natrium-freie Haarbehandlungsmittel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14702054

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14702054

Country of ref document: EP

Kind code of ref document: A1